Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEL&VAL in Severe Pulmonary Emphysema
NCT04018729Phase 3Recruiting
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Nov 2019
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial in pulmonary emphysema (2 arms), sponsored by Hospital de Clínicas de Porto Alegre. Primary endpoints: All-cause death at 6 months, Number of participants with worsening of dyspnea at 6 months and 3 more. Started Nov 2019; status: recruiting.
02
Conditions
pulmonary emphysema
Beyond the preview
Go deeper on NCT04018729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018729.